Cardiovascular Diseases

Cardiovascular Diseases

Accelerate Cardiovascular Drug Development with AniLocus: Leading Preclinical CRO Services

Discover the future of cardiovascular disease therapeutics with our in vivo preclinical research services. At AniLocus, we understand the urgency to find safe and effective treatments for millions affected by heart disease.

Our experienced team specializes in designing and directing pilot studies and IND-enabling in vivo studies, ensuring the efficacy and safety of pharmaceutical breakthroughs in cardiovascular medicine. As a growing contract research organization in the pharmaceutical industry, we offer comprehensive solutions for multiple cardiovascular disease indications.

Contact us to learn more about our in vivo research services and experience the power of pharma with AniLocus.

We stand for quality, safety & credibility. Our goal at Anilocus is to support you in the drug development process.

Contact us! Learn more about our in vivo services for cardiovascular disease therapies:

    Here at AniLocus, we provide in vivo preclinical contract research services for cardiovascular drug development for the following CVD indications:

    • Arrhythmia
    • Arterial Stenosis
    • Atherosclerosis
    • Atrial/Ventricular Septal Defects
    • Atrial Dilation/Atrial Fibrillation
    • Cardiotoxicity
    • Cerebral Stroke
    • Chemotherapy Induced Cardiomyopathy
    • Congenital Heart Diseases
    • Coronary Artery Disease
    • Heart Attack (Myocardial Infarction)
    • Heart Failure
    • Heart Transplantation
    • Hypertension/Hypotension
    • Ischemia
    • Kidney/Renal Failure
    • Myocarditis
    • Pulmonary Arterial Hypertension (PAH)
    • Pulmonary Heart Disease
    • Regenerative Cardiovascular Medicine
    • Rheumatic Heart Disease
    • Stroke
    • Ventricle Hypertrophy
    Sample data depicting model induction prior to treatment in animals collected at AniLocus for a preclinical cardiovascular drug development study.

    Figure 1. Cardiac remodeling in experimental animal group. This figure presents cardiac morphology data obtained from Wistar rats used for inducing cardiovascular disease models. While the normalized heart weight (heart weight to tibia length) showed a trend towards increased weight in the experimental animals (p=0.076), there were significant increases in both left ventricle anterior wall thickness and posterior wall thickness. Additionally, the left ventricle cross-sectional area exhibited a significant decrease. Collectively, these results suggest that the experimental animals undergoing cardiovascular disease model induction exhibit signs of cardiac remodeling and potential structural changes in the heart. Further investigation and analysis would be necessary to fully understand the implications of these changes as it relates to therapeutic intervention.

    Mouse Models for Cardiovascular Disease Drug Development:

    • ApoE Knockout Mice: An ideal model for studying Lipid-lowering drugs, anti-inflammatory agents, and atherosclerosis-targeted therapies.
    • LDL Receptor Knockout Mice: An ideal model for studying Statins, PCSK9 inhibitors, and lipid-modifying drugs.
    • ANGII-Infused Mice: An ideal model for studying ACE inhibitors, angiotensin receptor blockers (ARBs), and anti-hypertensive drugs.
    • Spontaneously Hypertensive Mice (SHR): An ideal model for studying Anti-hypertensive agents and drugs targeting hypertension-related complications.
    • Diabetic Mice Models (e.g., db/db or ob/ob mice): An ideal model for studying Anti-diabetic medications, insulin sensitizers, and cardiovascular drugs for diabetic complications.
    • Transgenic Mice Expressing Cardiac-Specific Mutations (e.g., Myh6-Cre mice): An ideal model for studying Targeted gene therapies and drugs to modulate cardiac function.
    • Ischemia/Reperfusion (I/R) Injury Models: An ideal model for studying Cardioprotective agents, anti-inflammatory drugs, and reperfusion strategies.

    Rat Models for Cardiovascular Disease Drug Development:

    • Spontaneously Hypertensive Rats (SHR): an ideal model for studying Anti-hypertensive drugs, renin-angiotensin-aldosterone system (RAAS) inhibitors, and vasodilators.
    • Doxorubicin-Induced Cardiotoxicity Rat Models: an ideal model for studying Cardioprotective agents, antioxidants, and drugs to mitigate chemotherapy-induced cardiac damage.
    • Myocardial Infarction (MI) Models (e.g., LAD Ligation): an ideal model for studying Cardioprotective compounds, stem cell therapies, and tissue regeneration strategies.
    • Pressure Overload Models (e.g., Aortic Banding): an ideal model for studying Anti-hypertensive medications, beta-blockers, and therapies to alleviate cardiac hypertrophy.
    • Diet-Induced Rat Models (e.g., High-Fat Diet): an ideal model for studying Lipid-lowering drugs, anti-inflammatory agents, and obesity-related cardiovascular treatments.
    • Heart Failure Rat Models (e.g., Coronary Artery Ligation): an ideal model for studying Heart failure medications, inotropic agents, and therapies targeting cardiac remodeling.
    • Renal Artery Stenosis Rat Models: an ideal model for studying Renin-angiotensin system (RAS) inhibitors, vasodilators, and drugs to improve renal function.

    These rodent models serve as valuable tools for studying various aspects of cardiovascular diseases and testing a wide range of therapeutic interventions, from novel drug candidates to established treatments.

    Researchers can contact our team for a consultation to determine the most appropriate model based on the specific cardiovascular condition and therapeutic focus of their drug development studies.

    Frequently Asked Questions about in vivo studies for cardiovascular therapeutics:

    In vivo studies for cardiovascular therapeutics involve experiments conducted within living organisms (typically rodents or larger animals) to assess the safety and efficacy of potential treatments for cardiovascular diseases. These studies aim to replicate the physiological conditions of the human cardiovascular system to evaluate drug candidates and therapeutic interventions.

    In vivo studies can cover a broad range of cardiovascular diseases, including hypertension, atherosclerosis, heart failure, arrhythmias, myocardial infarction, cardiomyopathies, and vascular disorders. Researchers use various animal models to mimic these conditions and assess potential therapeutic strategies.

    In vivo studies provide a critical bridge between preclinical research and clinical trials. They allow researchers to evaluate the safety and efficacy of cardiovascular drug candidates in a living organism, providing valuable insights into their pharmacological effects, potential side effects, and overall therapeutic potential.

    Common animal models include mice and rats for smaller-scale studies, as well as larger animals like rabbits, dogs, and pigs for studies that require a closer approximation to human physiology. Specific models are selected based on the cardiovascular disease being studied and the research objectives.

    At AniLocus, in vivo studies typically involve inducing a cardiovascular condition in animals (e.g., hypertension or myocardial infarction) and administering the test compound or therapy. Our team will monitor relevant parameters such as blood pressure, cardiac function, lipid profiles, and histopathological changes to assess treatment effects. All results are updated in real-time to laboratory notebooks that we provide you with full access to. Enabling you to virtually monitor the study.

    Key endpoints include changes in blood pressure, heart rate, cardiac contractility, vascular function, lipid profiles, cardiac biomarkers, echocardiographic measurements, and histological assessments of heart and vessel tissues. These endpoints help determine treatment effectiveness.

    Ethical treatment is crucial. Our researchers adhere to ethical guidelines, obtain appropriate ethical approvals (e.g., IACUC), and prioritize the welfare of research animals. Measures like anesthesia, pain management, and humane endpoints are essential. All of which are discussed with your team in depth during the planning stages of the study development.

    Our researchers adhere to regulatory guidelines and good laboratory practices (GLP) when conducting in vivo studies. These guidelines ensure data quality, accuracy, and compliance with regulatory requirements for subsequent clinical trials.

    Study timelines vary based on the specific research objectives and the complexity of the study. In vivo studies can range from several weeks to several months, encompassing study design, execution, data analysis, and reporting learn more about our guide to Study Timelines. Timelines should align with research goals and regulatory requirements.